General Information of Drug (ID: DM59ZDN)

Drug Name
Nesvacumab Drug Info
Synonyms REGN910; SAR307746
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM59ZDN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Angiopoietin-2 (ANGPT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Faricimab DM83SEB Diabetic macular edema 9B71.02 Approved [3]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [4]
Trebananib DMOG2X1 Ovarian cancer 2C73 Phase 3 [5]
RG7221 DM8J9DC Colorectal cancer 2B91.Z Phase 2 [6]
RO5520985 DMD3WNP Colorectal cancer 2B91.Z Phase 2 [7]
LY3127804 DMAC457 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 Trial [8]
REGN910-3 DMTBRPO Neovascular age-related macular degeneration 9B78.3Z Phase 2 [9]
CVX-060 DM03LWZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
BI 836880 DMRI6YT Neoplasm 2A00-2F9Z Phase 1 [11]
CVX-241 DMV74JC Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01271972) Study of Nesvacumab (REGN910/ SAR307746). U.S. National Institutes of Health.
2 Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869.
3 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
6 Company report (Roche pipeline: July 27, 2017)
7 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
10 Clinical pipeline report, company report or official report of CovX (2011).
11 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
12 Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.